"Quetiapine Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
| Descriptor ID |
D000069348
|
| MeSH Number(s) |
D02.886.680.702.500.500 D03.633.300.276.500
|
| Concept/Terms |
Quetiapine Fumarate- Quetiapine Fumarate
- Fumarate, Quetiapine
- Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt)
ICI 204,636- ICI 204,636
- 204,636, ICI
- ICI-204636
- ICI204636
- ICI 204636
- 204636, ICI
Quetiapine- Quetiapine
- 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
|
Below are MeSH descriptors whose meaning is more general than "Quetiapine Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Quetiapine Fumarate".
This graph shows the total number of publications written about "Quetiapine Fumarate" by people in this website by year, and whether "Quetiapine Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quetiapine Fumarate" by people in Profiles.
-
Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275.
-
Quetiapine protects the blood-brain barrier in traumatic brain injury. J Trauma Acute Care Surg. 2018 11; 85(5):968-976.
-
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry. 2015 Oct; 60(10):441-50.
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
-
A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014 Jul; 38(7):2113-8.
-
Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014 Jun; 34(3):359-64.
-
Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Drugs Aging. 2012 Oct; 29(10):807-17.
-
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Res. 2012 Dec 30; 200(2-3):126-32.
-
Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012 Apr; 10(2):83-94.
-
Tardive dyskinesia related to quetiapine and confirmed by a DAT scan. J Clin Psychopharmacol. 2011 Aug; 31(4):535-8.